XML 44 R10.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Revenues Revenues | 6 Months Ended
--- | ---
Jun. 30, 2018
Revenue from Contract with Customer [Abstract] |
Revenues | Revenues Product Revenues Revenues by product are summarized as follows:
| For the Three Months Ended June 30,
(In millions) | 2018 |  | 2017
| United States |  | Rest of World |  | Total |  | United States |  | Rest of World |  | Total
Multiple Sclerosis: |  |  |  |  |  |  |  |  |  |  |
TECFIDERA | $ | 825.8 |  |  | $ | 261.0 |  |  | $ | 1,086.8 |  |  | $ | 875.0 |  |  | $ | 235.6 |  |  | $ | 1,110.6 |
Interferon* | 444.7 |  |  | 180.8 |  |  | 625.5 |  |  | 501.7 |  |  | 188.9 |  |  | 690.6 |
TYSABRI | 265.5 |  |  | 201.7 |  |  | 467.2 |  |  | 289.4 |  |  | 206.6 |  |  | 496.0 |
FAMPYRA | — |  |  | 23.0 |  |  | 23.0 |  |  | — |  |  | 22.6 |  |  | 22.6 |
ZINBRYTA | — |  |  | — |  |  | — |  |  | — |  |  | 16.1 |  |  | 16.1 |
Spinal Muscular Atrophy: |  |  |  |  |  |  |  |  |  |  |
SPINRAZA | 205.9 |  |  | 216.8 |  |  | 422.7 |  |  | 194.8 |  |  | 8.1 |  |  | 202.9 |
Other Product Revenues: |  |  |  |  |  |  |  |  |  |  |
FUMADERM | — |  |  | 5.5 |  |  | 5.5 |  |  | — |  |  | 10.3 |  |  | 10.3 |
BENEPALI | — |  |  | 115.6 |  |  | 115.6 |  |  | — |  |  | 88.7 |  |  | 88.7 |
FLIXABI | — |  |  | 11.2 |  |  | 11.2 |  |  | — |  |  | 1.9 |  |  | 1.9 |
Total product revenues | $ | 1,741.9 |  |  | $ | 1,015.6 |  |  | $ | 2,757.5 |  |  | $ | 1,860.9 |  |  | $ | 778.8 |  |  | $ | 2,639.7 |
*Interferon includes AVONEX and PLEGRIDY.
| For the Six Months Ended June 30,
(In millions) | 2018 |  | 2017
| United States |  | Rest of World |  | Total |  | United States |  | Rest of World |  | Total
Multiple Sclerosis: |  |  |  |  |  |  |  |  |  |  |
TECFIDERA | $ | 1,554.7 |  |  | $ | 519.0 |  |  | $ | 2,073.7 |  |  | $ | 1,626.1 |  |  | $ | 442.7 |  |  | $ | 2,068.8 |
Interferon* | 816.0 |  |  | 359.8 |  |  | 1,175.8 |  |  | 966.5 |  |  | 372.4 |  |  | 1,338.9 |
TYSABRI | 515.2 |  |  | 414.1 |  |  | 929.3 |  |  | 594.9 |  |  | 446.1 |  |  | 1,041.0 |
FAMPYRA | — |  |  | 47.4 |  |  | 47.4 |  |  | — |  |  | 43.1 |  |  | 43.1 |
ZINBRYTA | — |  |  | 1.4 |  |  | 1.4 |  |  | — |  |  | 26.8 |  |  | 26.8 |
Spinal Muscular Atrophy: |  |  |  |  |  |  |  |  |  |  |
SPINRAZA | 393.9 |  |  | 392.7 |  |  | 786.6 |  |  | 241.2 |  |  | 9.1 |  |  | 250.3 |
Hemophilia: |  |  |  |  |  |  |  |  |  |  |
ELOCTATE | — |  |  | — |  |  | — |  |  | 42.2 |  |  | 6.2 |  |  | 48.4 |
ALPROLIX | — |  |  | — |  |  | — |  |  | 21.0 |  |  | 5.0 |  |  | 26.0 |
Other Product Revenues: |  |  |  |  |  |  |  |  |  |  |
FUMADERM | — |  |  | 12.5 |  |  | 12.5 |  |  | — |  |  | 20.0 |  |  | 20.0 |
BENEPALI | — |  |  | 236.5 |  |  | 236.5 |  |  | — |  |  | 154.0 |  |  | 154.0 |
FLIXABI | — |  |  | 17.8 |  |  | 17.8 |  |  | — |  |  | 2.5 |  |  | 2.5 |
Total product revenues | $ | 3,279.8 |  |  | $ | 2,001.2 |  |  | $ | 5,281.0 |  |  | $ | 3,491.9 |  |  | $ | 1,527.9 |  |  | $ | 5,019.8 |
*Interferon includes AVONEX and PLEGRIDY. We recognized revenues from two wholesalers accounting for 32.5% and 18.6% of gross product revenues for the three months ended June 30, 2018, and 33.2% and 17.3% of gross product revenues for the six months ended June 30, 2018. We recognized revenues from two wholesalers accounting for 34.3% and 22.8% of gross product revenues for the three months ended June 30, 2017, and 35.5% and 21.1% of gross product revenues for the six months ended June 30, 2017. An analysis of the change in reserves for discounts and allowances is summarized as follows:
(In millions) | Discounts |  | Contractual Adjustments |  | Returns |  | Total
Balance, as of December 31, 2017 | $ | 109.6 |  |  | $ | 606.0 |  |  | $ | 46.0 |  |  | $ | 761.6 |
Current provisions relating to sales in current year | 333.2 |  |  | 1,288.0 |  |  | 11.4 |  |  | 1,632.6 |
Adjustments relating to prior years | (0.3 | ) |  | 7.4 |  |  | 2.6 |  |  | 9.7 |
Payments/credits relating to sales in current year | (222.3 | ) |  | (731.9 | ) |  | — |  |  | (954.2 | )
Payments/credits relating to sales in prior years | (101.0 | ) |  | (469.6 | ) |  | (13.5 | ) |  | (584.1 | )
Balance, as of June 30, 2018 | $ | 119.2 |  |  | $ | 699.9 |  |  | $ | 46.5 |  |  | $ | 865.6 |
The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:
(In millions) | As of June 30, 2018 |  | As of December 31, 2017
Reduction of accounts receivable | $ | 162.8 |  |  | $ | 189.6 |
Component of accrued expenses and other | 702.8 |  |  | 572.0 |
Total reserves | $ | 865.6 |  |  | $ | 761.6 |
Revenues from Anti-CD20 Therapeutic Programs Revenues from anti-CD20 therapeutic programs are summarized as follows:
| For the Three Months Ended June 30, |  | For the Six Months Ended June 30,
(In millions) | 2018 |  | 2017 |  | 2018 |  | 2017
Biogen’s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA | $ | 359.0 |  |  | $ | 347.5 |  |  | $ | 708.6 |  |  | $ | 671.0 |
Other revenues from anti-CD20 therapeutic programs | 131.4 |  |  | 49.6 |  |  | 225.0 |  |  | 66.7 |
Total revenues from anti-CD20 therapeutic programs | $ | 490.4 |  |  | $ | 397.1 |  |  | $ | 933.6 |  |  | $ | 737.7 |
For additional information on our collaboration with Genentech, please read Note 20, Collaborative and Other Relationships, to our consolidated financial statements included in our 2017 Form 10-K. Other Revenues Other revenues are summarized as follows:
| For the Three Months Ended June 30, |  | For the Six Months Ended June 30,
(In millions) | 2018 |  | 2017 |  | 2018 |  | 2017
Revenues from collaborative and other relationships: |  |  |  |  |  |  |
AbbVie | $ | (2.5 | ) |  | $ | (3.9 | ) |  | $ | (7.2 | ) |  | $ | (9.8 | )
Samsung Bioepis and other | 14.7 |  |  | 12.9 |  |  | 32.6 |  |  | 25.1 |
Other royalty and corporate revenues: |  |  |  |  |  |  |
Royalty | 17.3 |  |  | 11.8 |  |  | 27.9 |  |  | 37.3 |
Other corporate | 79.1 |  |  | 20.8 |  |  | 219.7 |  |  | 79.0 |
Total other revenues | $ | 108.6 |  |  | $ | 41.6 |  |  | $ | 273.0 |  |  | $ | 131.6 |
For additional information related to our collaborations with AbbVie and Samsung Bioepis, please read Note 18, Collaborative and Other Relationships, to these condensed consolidated financial statements.

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -URI http://asc.fasb.org/topic&trid=49130388 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -URI http://asc.fasb.org/topic&trid=2122369 + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration